23-06-12	Piper Sandler Initiates InspireMD at Overweight With $3 Price Target	MT
23-05-17	Alliance Global Adjusts Price Target on InspireMD to $4.75 From $5.15, Maintains Buy Rating	MT

More recommendations

Managers and Directors: InspireMD

Manager	Title	Age	Since
Marvin Slosman CEO	Chief Executive Officer	62	2019-12-31
Michael Lawless DFI	Director of Finance/CFO	58	2025-06-29
Shany Barel CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Paul Stuka CHM	Chairman	71	2017-06-01
Michael Berman BRD	Director/Board Member	68	2013-02-06
Marvin Slosman BRD	Director/Board Member	62	2019-12-31

More insiders

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrows Top Investments!

SEIZE THE OFFER!

Market Cap	34.19M 29.53M 27.21M 25.47M 47.74M 3.25B 48.48M 321M 125M 1.58B 128M 126M 5.48B	P/E Ratio 2026 *	-	P/E Ratio 2027 *	-
Enterprise Value	34.19M 29.53M 27.21M 25.47M 47.74M 3.25B 48.48M 321M 125M 1.58B 128M 126M 5.48B	EV / Sales 2026 *	3.3x	EV / Sales 2027 *	1.56x
Free-Float	80.17%	Yield 2026 *	-	Yield 2027 *	-

06-08	Inspiremd Enrolls First Patient in Cguardians Iii Pivotal Study of Switchguard Neuro Protection System for Use in Tcar Procedures	CI
05-22	InspireMD, Inc. Announces Not Seek Re-Election of Paul Stuka as Director	CI
05-13	InspireMD, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 04:20 PM
05-04	InspireMD, Inc., Q1 2026 Earnings Call, May 04, 2026
05-04	InspireMD, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-01	FDA Approves InspireMD's Application to Initiate Study of Neuro Protection System -- Update	DJ
05-01	InspireMD Says FDA Approved Application to Begin SwitchGuard Neuro Protection System CGUARDIANS III Study	MT
05-01	InspireMD Withdraws Guidance, Recalls CGuard Prime	DJ
05-01	InspireMD, Inc. Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System	CI
05-01	Inspiremd Inc Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the Switchguard Neuro Protection System	CI
03-18	InspireMD, Inc., Q4 2025 Earnings Call, Mar 18, 2026
03-18	InspireMD, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-18	InspireMD, Inc. Provides Earnings Guidance for the Full Year 2026	CI

06-12	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
06-11	InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures	AQ
06-08	InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures	AQ
05-06	InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference	AQ
05-04	InspireMD : May 2026 Investor Deck	PU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INSPIREMD	-3.81%	+32.01%	-	-	34.19M
STRYKER CORPORATION	-1.26%	+2.65%	-17.92%	+4.70%	120B
SMITH & NEPHEW PLC	+0.38%	-0.35%	+4.85%	-9.27%	12.9B
GLAUKOS CORPORATION	+1.08%	+5.81%	+28.87%	+91.21%	7.44B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+1.87%	-4.66%	-46.88%	-70.47%	4.2B
DOUBLE MEDICAL TECHNOLOGY INC.	+2.06%	+4.10%	+11.98%	+33.22%	2.55B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	+5.46%	+10.04%	-15.76%	-14.88%	1.8B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	+1.67%	-5.73%	+5.08%	-11.03%	1.66B
L&C BIO CO.,LTD	-8.89%	-10.79%	+152.96%	+121.29%	1.37B
Average	-0.09%	+0.88%	+15.40%	+18.09%	18.95B
Weighted average by Cap.	-0.74%	+1.76%	-12.17%	+6.80%

	2026 *	2027 *
Net sales	10.38M 8.96M 8.26M 7.73M 14.49M 986M 14.71M 97.5M 38.02M 480M 38.94M 38.11M 1.66B	21.92M 18.93M 17.44M 16.33M 30.6M 2.08B 31.07M 206M 80.3M 1.01B 82.25M 80.5M 3.51B
Net income	-	-
Net Debt	-	-

InspireMD Stock NYSE

Stocks

Medical Equipment, Supplies & Distribution

Valuation: InspireMD

Latest news : InspireMD

Last Transcript: InspireMD

Analysts' recommendations: InspireMD

Press Releases: InspireMD

Quotes and Performance

Managers and Directors: InspireMD

Medical Devices & Implants

Financials

Company Profile